Integra Lifesciences Holdings (IART) Cash & Equivalents (2009 - 2026)
Integra Lifesciences Holdings (IART) posted Cash & Equivalents of $214.4 million for Q2 2026, down 9.46% sequentially from $236.8 million in Q1 2026, and down 1.61% YoY from $217.9 million in Q2 2025.
Integra Lifesciences Holdings (IART) Cash & Equivalents (2009 - 2026) Analysis & Trends
Integra Lifesciences Holdings has reported Cash & Equivalents for 18 years, with the latest figure at $214.4 million in Q2 2026.
- Quarterly Cash & Equivalents fell 1.61% year-over-year to $214.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $214.4 million (down 1.61% YoY) and the FY2025 annual result came in at $235.0 million, down 4.6% from the prior year.
- Cash & Equivalents retreated to $214.4 million in Q2 2026 per IART's latest filing, from $236.8 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $591.9 million in Q1 2024 and troughed at $214.4 million in Q2 2026.
- A 5-year average of $313.0 million and a median of $260.1 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 92.57% in 2024, then tumbled 59.6% in 2025.
- Over 5 years, Cash & Equivalents stood at $456.7 million in 2022, then tumbled by 39.47% to $276.4 million in 2023, then dropped by 10.86% to $246.4 million in 2024, then decreased by 4.6% to $235.0 million in 2025, then decreased by 8.78% to $214.4 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $214.4 million, $236.8 million, and $235.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 5.10 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 3.39 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.95 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 539.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 2.91 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 1.11 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 2.11 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 3.25 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 482.30 Mn |
| 10 | Integra Lifesciences Holdings | 1.28 Bn | 1.01 Bn | 219.74 Mn | 214.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 214.42 Mn |
| Mar 31, 2026 | 236.81 Mn |
| Dec 31, 2025 | 235.05 Mn |
| Sep 30, 2025 | 232.20 Mn |
| Jun 30, 2025 | 217.91 Mn |
| Mar 31, 2025 | 239.10 Mn |
| Dec 31, 2024 | 246.38 Mn |
| Sep 30, 2024 | 215.20 Mn |
| Jun 30, 2024 | 215.24 Mn |
| Mar 31, 2024 | 591.91 Mn |
| Dec 31, 2023 | 276.40 Mn |
| Sep 30, 2023 | 273.73 Mn |
| Jun 30, 2023 | 309.19 Mn |
| Mar 31, 2023 | 307.37 Mn |
| Dec 31, 2022 | 456.66 Mn |
| Sep 30, 2022 | 511.94 Mn |
| Jun 30, 2022 | 447.15 Mn |
| Mar 31, 2022 | 407.09 Mn |
| Dec 31, 2021 | 513.45 Mn |
| Sep 30, 2021 | 470.23 Mn |